Jill Heemskerk

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Teaching old drugs new tricks. Meeting of the Neurodegeneration Drug Screening Consortium, 7-8 April 2002, Washington, DC, USA
    Jill Heemskerk
    Technology Development Program, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Trends Neurosci 25:494-6. 2002
  2. ncbi request reprint High throughput drug screening
    Jill Heemskerk
    National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 5:19-21. 2004
  3. ncbi request reprint Spinal muscular atrophy: classification, diagnosis, management, pathogenesis, and future research directions
    Felina V Kostova
    Medical University of South Carolina, Charleston, South Carolina, USA
    J Child Neurol 22:926-45. 2007
  4. ncbi request reprint From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials
    Jill Heemskerk
    Technology Development Program, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland 20892, USA
    Nat Neurosci 5:1027-9. 2002
  5. ncbi request reprint Screening existing drugs for neurodegeneration: The National Institute of Neurologic Disorders and Stroke (NINDS) model
    Jill Heemskerk
    Technology Development at the NINDS and Spinal Muscular Atrophy Project and the NINDS High Throughput Drug Screening Facility for Neurodegeneration, USA
    Retina 25:S56-S57. 2005

Collaborators

  • Bernard Ravina
  • Felina V Kostova
  • CHRISTINE DIDONATO
  • Susan Iannaccone
  • Kathryn Swoboda
  • Bernard L Maria
  • Virginia C Williams

Detail Information

Publications5

  1. ncbi request reprint Teaching old drugs new tricks. Meeting of the Neurodegeneration Drug Screening Consortium, 7-8 April 2002, Washington, DC, USA
    Jill Heemskerk
    Technology Development Program, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Trends Neurosci 25:494-6. 2002
    ..Meeting of the Neurodegeneration Drug Screening Consortium, held on 7-8 April 2002, Washington, DC, USA...
  2. ncbi request reprint High throughput drug screening
    Jill Heemskerk
    National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 5:19-21. 2004
  3. ncbi request reprint Spinal muscular atrophy: classification, diagnosis, management, pathogenesis, and future research directions
    Felina V Kostova
    Medical University of South Carolina, Charleston, South Carolina, USA
    J Child Neurol 22:926-45. 2007
    ..This article summarizes the presentations and includes the verbatim edited transcript of question-and-answer sessions...
  4. ncbi request reprint From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials
    Jill Heemskerk
    Technology Development Program, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland 20892, USA
    Nat Neurosci 5:1027-9. 2002
  5. ncbi request reprint Screening existing drugs for neurodegeneration: The National Institute of Neurologic Disorders and Stroke (NINDS) model
    Jill Heemskerk
    Technology Development at the NINDS and Spinal Muscular Atrophy Project and the NINDS High Throughput Drug Screening Facility for Neurodegeneration, USA
    Retina 25:S56-S57. 2005